Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study

SIMPLE SUMMARY: This was a multicenter, single-arm, phase II study comprising two protocol treatments. Patients were enrolled after craniotomy or biopsy and initiated the concurrent phase; oral daily temozolomide concomitant with radiation therapy during the first 6 weeks of treatment. Bevacizumab w...

Descripción completa

Detalles Bibliográficos
Autores principales: Nagane, Motoo, Ichimura, Koichi, Onuki, Ritsuko, Narushima, Daichi, Honda-Kitahara, Mai, Satomi, Kaishi, Tomiyama, Arata, Arai, Yasuhito, Shibata, Tatsuhiro, Narita, Yoshitaka, Uzuka, Takeo, Nakamura, Hideo, Nakada, Mitsutoshi, Arakawa, Yoshiki, Ohnishi, Takanori, Mukasa, Akitake, Tanaka, Shota, Wakabayashi, Toshihiko, Aoki, Tomokazu, Aoki, Shigeki, Shibui, Soichiro, Matsutani, Masao, Ishizawa, Keisuke, Yokoo, Hideaki, Suzuki, Hiroyoshi, Morita, Satoshi, Kato, Mamoru, Nishikawa, Ryo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688169/
https://www.ncbi.nlm.nih.gov/pubmed/36428615
http://dx.doi.org/10.3390/cancers14225522

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688169/
https://www.ncbi.nlm.nih.gov/pubmed/36428615
http://dx.doi.org/10.3390/cancers14225522

Ejemplares similares